Care este prețul pentru Novo Nordisk A/S (NOVO-B)

Prețul pentru Novo Nordisk A/S (NOVO-B) este $47.55

Care este capitalizarea de piață pentru Novo Nordisk A/S (NOVO-B)

Capitalizarea de piață pentru Novo Nordisk A/S (NOVO-B) este $211.25B

Venituri Novo Nordisk A/S (NOVO-B)

Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.

An	Venituri	Schimbă
Nu sunt suficiente date pentru perioada selectată.

Venituri

Schimbă

Nu sunt suficiente date pentru perioada selectată.

Companie	Venituri	Diferență de venituri	Țara
Eli Lilly and Company LLY.US	$79.67B	64.10%	US
Johnson & Johnson JNJ.US	$97.93B	101.72%	US
AbbVie Inc. ABBV.US	$64.39B	32.62%	US
Roche Holding AG RO.SW	$77.52B	59.67%	CH
Merck & Co., Inc. MRK.US	$66.40B	36.77%	US

Companie

Venituri

Diferență de venituri

Țara